Can GDF-15 be Used to Assess ventricular recovery following Left Ventricular Assist Device Therapy?
|Nandini Nair1* and Enrique Gongora2|
|1Division of Cardiology, Department of Medicine, Texas Tech Health Sciences Center, Lubbock, TX 79430, USA|
|2Memorial Cardiac and Vascular Institute, Hollywood, FL 33021, USA|
|Corresponding Author :||Nandini Nair MD
PhD, FSVM, FACC, FACP
Division of Cardiology, Department of Medicine
Texas Tech Health Sciences Center
Lubbock, TX 79430, USA
E-mail: [email protected]
|Received September 27, 2015; Accepted September 29, 2015; Published September 30, 2015|
|Citation:Nair N, Gongora E (2015) CCan GDF-15 be used to Assess Ventricular Recovery Following Left Ventricular Assist Device Therapy? J Cell Sci Ther S8: 007. doi:10.4172/2157-7013.S8-007|
|Copyright: © 2015 Nair N, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.|
|Related article at Pubmed, Scholar Google|
With the rising incidence of end stage heart failure and the stagnating pool of donors, left ventricular assist device (LVAD) therapy has emerged as a bridge to recovery/transplant or as destination therapy. However, the number of patients who actually undergo device explant as a result of ventricular recovery happens to be highly variable at the present time [1,2]. Ventricular recovery is a complex phenomenon influenced by several factors such as the etiology/duration of heart failure, extent of scarring and fibrosis of the myocardium at the time of implantation and adjunct medical management protocol tailored for recovery immediately post device implantation.